Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Jiao Y, Moya B, Chen MJ, Zavascki AP, Tsai H, Tao X, Sutaria DS, Louie A, Boyce JD, Deveson Lucas D, Kim TH, Tsuji BT, Bonomo RA, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00425-19. doi: 10.1128/AAC.00425-19. Print 2019 Jul.

PMID:
30988147
2.

Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L.

Cochrane Database Syst Rev. 2014 Jan 7;(1):CD003344. doi: 10.1002/14651858.CD003344.pub3. Review.

3.

Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003344. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD003344.

PMID:
16437452
4.

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia.

Paul M, Soares-Weiser K, Grozinsky S, Leibovici L.

Cochrane Database Syst Rev. 2003;(3):CD003038. Review. Update in: Cochrane Database Syst Rev. 2013;6:CD003038.

PMID:
12917941
5.

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia.

Paul M, Soares-Weiser K, Grozinsky S, Leibovici L.

Cochrane Database Syst Rev. 2002;(2):CD003038. Review. Update in: Cochrane Database Syst Rev. 2003;(3):CD003038.

PMID:
12076467
6.

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.

Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L.

Cochrane Database Syst Rev. 2013 Jun 29;(6):CD003038. doi: 10.1002/14651858.CD003038.pub2. Review.

7.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Review.

PMID:
30712199
8.

Extended-interval aminoglycoside administration for children: a meta-analysis.

Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP.

Pediatrics. 2004 Jul;114(1):e111-8.

PMID:
15231982
9.

The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.

Falagas ME, Matthaiou DK, Bliziotis IA.

J Antimicrob Chemother. 2006 Apr;57(4):639-47. Epub 2006 Feb 24. Review.

PMID:
16501057
10.

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.

Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L.

BMJ. 2004 Mar 20;328(7441):668. Epub 2004 Mar 2. Review. Erratum in: BMJ. 2004 Apr 10;328(7444):884.

11.

Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials.

Bliziotis IA, Michalopoulos A, Kasiakou SK, Samonis G, Christodoulou C, Chrysanthopoulou S, Falagas ME.

Mayo Clin Proc. 2005 Sep;80(9):1146-56.

PMID:
16178494
12.

Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.

Sharma R, Park TE, Moy S.

Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2. Review.

PMID:
26948862
13.

Empiric antibiotic therapy for granulocytopenic cancer patients.

Schimpff SC.

Am J Med. 1986 May 30;80(5C):13-20.

PMID:
3521270
14.

β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.

Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME.

Int J Antimicrob Agents. 2013 Apr;41(4):301-10. doi: 10.1016/j.ijantimicag.2012.12.006. Epub 2013 Feb 12. Review.

PMID:
23410791
15.

Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.

Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME.

Clin Infect Dis. 2005 Jul 15;41(2):149-58. Epub 2005 May 31.

PMID:
15983909
16.

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.

Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, Pitlik SD.

Antimicrob Agents Chemother. 1997 May;41(5):1127-33. Erratum in: Antimicrob Agents Chemother 1997 Nov;41(11):2595.

17.

Dual antibiotics for bronchiectasis.

Felix LM, Grundy S, Milan SJ, Armstrong R, Harrison H, Lynes D, Spencer S.

Cochrane Database Syst Rev. 2018 Jun 11;6:CD012514. doi: 10.1002/14651858.CD012514.pub2. Review.

18.

Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.

DeJace P, Klastersky J.

Am J Med. 1986 Jun 30;80(6B):29-38. Review.

PMID:
3524218
19.

Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms.

Martínez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, Pitart C, Sterzik H, Lopez J, Mensa J.

Antimicrob Agents Chemother. 2010 Sep;54(9):3590-6. doi: 10.1128/AAC.00115-10. Epub 2010 Jun 28.

20.

Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials.

Marcus R, Paul M, Elphick H, Leibovici L.

Int J Antimicrob Agents. 2011 Jun;37(6):491-503. doi: 10.1016/j.ijantimicag.2010.11.029. Epub 2011 Feb 2. Review.

PMID:
21292449

Supplemental Content

Support Center